Product Description
Dermorphin demonstrates significantly stronger μ-opioid receptor agonism compared to classical opioid ligands, making it invaluable for research on pain perception, analgesic pathways, and CNS receptor pharmacodynamics.
Its selectivity for μ-opioid receptors allows researchers to investigate receptor-specific signaling, downstream pathways, and interactions without excessive cross-activity at other opioid receptors.
The presence of D-Ala in its sequence enhances receptor affinity and resistance to enzymatic degradation, offering a unique model for studying peptide stability and bioactivity.
Dermorphin is widely used to explore central nervous system responses, neurochemical pathways, and the molecular mechanisms underlying analgesia and nociception.
Because of its potency and structural uniqueness, Dermorphin serves as a reference molecule in the design and evaluation of next-generation opioid-based therapeutics.
Compared to many peptides, Dermorphin demonstrates superior stability and predictable receptor activation, supporting reliable, repeatable research outcomes.
| Parameter | Description |
| CAS Number | 77614-16-5 |
| Product Name | Dermorphin |
| Molecular Formula | C₄₀H₅₁N₇O₁₀ |
| Molecular Weight | 751.87 g/mol |
| Amino Acid Sequence | H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂ |
| Appearance | White to off-white lyophilized powder |
| Storage | Store at –20°C, protected from light |
| Specification | Option |
| Purity | ≥98% (HPLC) |
| Form | Lyophilized powder |
| Vial Sizes | 1 mg, 5 mg, 10 mg, 50 mg (custom sizes available) |
| Packaging | Sterile sealed vials; moisture-resistant, temperature-controlled packaging |
| Shelf Life | 24 months when stored under recommended conditions |
Dermorphin is used extensively in preclinical models to study pain pathways, opioid receptor activity, and novel analgesic mechanisms.
Its potent CNS activity makes Dermorphin an important molecule in research focusing on receptor signaling, neuronal response patterns, and neurochemical regulation.
Researchers utilize Dermorphin to evaluate μ-opioid receptor binding characteristics, receptor selectivity profiles, and signaling dynamics.
Dermorphin’s high potency and stability make it a template for designing modified peptide ligands with enhanced therapeutic potential.
Its strong contrast with conventional opioids offers a valuable benchmark for comparing efficacy, receptor activation, and side-effect profiles.
